Invesco Financials S&P US Select Sector UCITS ETF (XLFS) Chart

Greatland Gold PLC (AIM:GGP, OTC:GRLGF) CEO Shaun Day talked with Proactive about the company’s latest mineral resource update and its upcoming dual listing on the ASX. The update confirms 10.2 million ounces of gold and 387,000 tonnes of copper, significantly expanding the company's resource base. Day highlighted that more than 55% of these resources fall under the measured and indicated category, allowing for future conversion to reserves. The company has also added 3.2 million ounces of gold and 117,000 tonnes of copper at the Telfer mine, strengthening its position in the market. "The size of the prize here in terms of life extension is really significant," he stated. The CEO also discussed Greatland Gold’s upcoming ASX listing, set for June 2025, which will broaden investor access and enhance market visibility. "We believe this cross-listing will unlock new demand from Australian investors and provide indexation benefits while maintaining our London listing," Day explained. Additionally, the company is ramping up exploration with six drill rigs in operation, aiming to further extend Telfer’s mine life and identify new mineralisation zones. Upcoming milestones include the March quarterly results in April and a reserve update later in the year. Stay tuned for more updates from Proactive. If you found this video helpful, give it a like, subscribe to our channel, and turn on notifications for the latest insights. #GreatlandGold #GoldMining #MiningStocks #ASXListing #GoldInvesting #TelferMine #CopperMining #MiningNews #ResourceUpdate #GoldStocks

Sona Nanotech Inc chief medical officer Dr Carman Giacomantonio takes Proactive's Stephen Gunnion through the company’s latest findings related to its targeted hyperthermia therapy (THT), which he described as showing “very enabling immunogenic” effects in recent experiments. The THT platform works by delivering controlled heat to the core of a tumour, triggering a natural cell death response and activating the body's immune system. Giacomantonio explained that this process exposes tumour proteins to immune cells, increasing the chance that they will be recognised and attacked. He noted that “all cancer cells have this kind of evolutionary quality” of resisting cell death, but THT stresses the cells enough to induce it. These latest experiments build on data first shared in December, with increased sample sizes confirming the reproducibility of the results. According to Giacomantonio, tumours treated with saline or checkpoint inhibitors alone continued to grow, while those exposed to THT and the immune modulator PD1 showed complete inhibition or reduction in growth. Looking ahead, he said the company plans to expand testing to demonstrate systemic immune responses, with the goal of treating metastatic cancers by targeting a single tumour site. Visit Proactive's YouTube channel for more company updates. Don’t forget to give this video a like, subscribe to the channel, and enable notifications so you never miss future content. #SonaNanotech #CancerTherapy #TargetedHyperthermia #Immunotherapy #BiotechNews #TumourTreatment #CancerResearch #MedicalInnovation #PD1Inhibitor #MetastaticCancer #HealthcareTech #OncologyBreakthrough

Crucial Innovations Corp CEO Jon-Paul Doran talked with Proactive's Stephen Gunnion about the company’s expansion. The US-based firm, soon to be quoted on the OTC markets, operates a vertically integrated business with cultivation facilities in South Africa and a dispensary in the UK. Doran highlighted the company’s seed-to-sale model, which ensures control over quality and supply. He explained that their proprietary genetics provide an edge in the medicinal market, enabling precision medicine for patients. With a low-cost production base in South Africa and a growing European and UK market focus, the company is positioned for long-term growth. Discussing the decision to list in the US, Doran cited higher investor interest and market potential compared to the UK. He expects Crucial Innovations to start trading on the OTCQB by mid-to-late April, with a plan to uplist to the OTCQX and eventually Nasdaq. The company also has an aggressive acquisition strategy, aiming to acquire high-efficiency operators to boost its net asset value, revenue, and human capital. “We want to be a driver of consistent quality,” Doran emphasized, highlighting South Africa’s progressive stance and the expertise of its cultivation specialists. Watch the full interview to learn more about Crucial Innovations’ vision and upcoming milestones. Don't forget to like, subscribe, and turn on notifications for more updates from Proactive! #CrucialInnovations #OTCMarkets #Investing #CannabisIndustry #JPdoran #SouthAfrica #SeedToSale #OTCQB #OTCQX #Nasdaq #ProactiveInvestors

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the company has been awarded a grant from the Medical CBRN Defense Consortium to support the continued development of its next-generation vaccine candidate. MCDC is a consortium comprising industrial, academic, and non-profit organizations that assist the U.S. government in advancing medical solutions to protect against chemical, biological, radiological, and nuclear threats. Dr. Lederman explained that the vaccine candidate is being developed as an improved immunization option for mpox and smallpox, with the potential for delivery via innovative alternative methods designed to enhance patient compliance, ease of administration, and overall tolerability. The MCDC grant will support comprehensive market analyses, target market identification, and commercialization planning for both private and government sectors. The investigational vaccine is a minimally replicating live-virus formulation based on a modified orthopoxvirus. It has demonstrated the ability to provide single-dose immune protection against mpox in preclinical studies while offering improved tolerability compared to traditional live-virus vaccines. Previous studies have also shown its effectiveness in protecting animals from lethal intratracheal exposure to a more virulent strain of the mpox virus. Tonix is currently preparing for Phase 1 clinical trials in both the United States and Kenya. Kenya, which is on the outskirts of an MPOX outbreak in Africa, presents an opportunity to test the vaccine in an area with a growing case burden. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors